Anavex Life Sciences Corp (AVXL)

[bas2020]

I guess I'm not following... seems each indication (PD, Epilepsy, MS, Retts, FTD) require separate trials, where some would qualify as ODD (FTD and perhaps Retts). So, why not apply for ODD with 2-73, as well as 3-71, for these two conditions?

Perhaps what you're saying, is that since 2-73 is already in trials for Alz, then when it gets FDA approval it can be given off label for other CNS disorders, without additional trials?

Thanks